Darrell E. White

It is September once again, time for us to review the state of the anti-inflammatory landscape in the world of dry eye disease.Boy, it sure seems like I have done a lot of these things. You might think that there is not a whole lot more to say, and in some ways, I would agree. But as sure as the wind quickens here on the North Coast and the temperatures become more bracing, it looks like this

It is autumn on the North Coast. Longer nights lead to deeper insights as we contemplate the winter solstice. As usual, I am thinking dry eye. It is, as they say, how I roll.If you recall, I promised one of the guests at a dinner presentation that I would spend a column or four on topics that touched on the basics of diagnosing and treating dry eye disease (DED). While this doctor may have been

As promised, here is the fourth installment of the dry eye disease “Back to Basics” series requested by an audience member at a dinner presentation I gave last winter.In part 1, we took a look at normal tears, of which we have three types: baseline, psychic and reflex. Part 2 was snuck into the annual September column on the state of anti-inflammatory treatment of dry eye disease

’Twas a time, not so very long ago, when eye doctors treating dry eye disease had heart-to-hearts about how we should discuss the latency between onset of treatment and when patients would finally begin to feel some relief.

Man, did that year go fast!It seems like it was only 2 months ago that Miebo (perfluorohexyloctane ophthalmic solution, Bausch + Lomb) and Xdemvy (lotilaner ophthalmic solution 0.25%, Tarsus Pharmaceuticals) were approved by the FDA and entered the market. It was the second half of 2023, of course, when they made their debut. It is truly amazing how quickly both medications have become fixtures

Happy New Year! How was your holiday season?As usual, I am sitting down to write this column long before any of the stuff I am asking about has actually happened for me. It is 19 degrees in Cleveland today, and Lake Erie is a roiling cauldron of seasonal agitation. Kinda like me, to be honest. At my latitude, the fourth quarter of each year is by far the busiest for eye doctors of all stripes.

We’re still in the first quarter of the insurance plan year.

OK. One last column on the whole “why is my medicine so expensive” thing, and then I am done. Promise.It has come to my attention that one of my Healio | OSN pieces was “borrowed” to support a manufacturer’s cash-pay strategy for its dry eye disease (DED) medication. I am flattered, of course, and also grateful for the opportunity this provides to shed some light on

Dry eye continues to be a hot spot when it comes to new diagnostic and therapeutic modalities.Large established companies and small startups alike continue to develop new products and bring them to market. To be sure, some of the new offerings are less new and more “me too.” I mean, how many more different options do we really need in the cyclosporine A space? I would be perfectly

Boy, I know that there are some really terrible jobs in the extended health care universe, but it sure seems like one of them has to be the pharmaceutical sales representative.You know, the sales reps who are customer-facing foot soldiers and spend their workdays in the space between the folks who make medicine and medical devices and the people who prescribe and use them.